Juvenile myelomonocytic leukemia pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 12: | Line 12: | ||
{{Hematological malignancy histology}} | {{Hematological malignancy histology}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 16:39, 9 August 2012
|
Juvenile myelomonocytic leukemia Microchapters |
|
Differentiating Juvenile myelomonocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Juvenile myelomonocytic leukemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Juvenile myelomonocytic leukemia pathophysiology |
|
Juvenile myelomonocytic leukemia pathophysiology in the news |
|
Risk calculators and risk factors for Juvenile myelomonocytic leukemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Genetics
About 80% of JMML patients have some sort of genetic abnormality in their leukemia cells that can be identified with laboratory testing. This includes:
- 15-20% of patients with neurofibromatosis 1 (NF1)
- 25% of patients with mutations in one of the RAS family of oncogenes (only in their leukemia cells)
- Another 35% of patients with a mutation in a gene called PTPN11 (again, only in their leukemia cells).